The US Food and Drug Administration (FDA) has granted approval to France-based Sanofi for its blood-disorder drug Cablivi (caplacizumab-yhdp), it was reported yesterday.
The product has been approved in combination with plasma exchange and immunosuppression to treat acquired thrombotic thrombocytopenic purpura in adults. The product is said to be the first FDA-approved therapy for the treatment of acquired thrombotic thrombocytopenic purpura. It targets von Willebrand factor (vWF), a protein in the blood that involves in haemostasis. It has been designed to inhibit the interaction between vWF and platelets.
The product's approval was based on data from the Hercules multicentre, randomised, double-blind, placebo-controlled phase three clinical study. The company said that the treatment with Cablivi in combination with plasma exchange and immunosuppression resulted in a significantly shorter time to platelet count response against plasma exchange and immunosuppression alone, which is a primary efficacy endpoint.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study